79 results about "Restless legs syndrome" patented technology

A method for treating essential tremor or restless leg syndrome using spinal cord stimulation includes implanting a lead near a spinal cord of a patient. The lead includes a plurality of electrodes disposed on a distal end of the lead and electrically coupled to at least one contact terminal disposed on a proximal end of the lead. Electrical signals are provided from a control module coupled to the lead to stimulate a portion of the spinal cord of the patient using at least one of the electrodes. The electrical signals reduce, alleviate, or eliminate at least one adverse effect of essential tremor or restless leg syndrome.

A method for the treatment of Restless Leg Syndrome (RLS), which comprises administering an alpha2-agonist and a second agent selected from the group consisting of the dopamine agonists, opioids, benzodiazepines and the combination of L-DOPA plus a decarboxylase inhibitor.

Disclosed are methods for the treatment of Restless Legs Syndrome comprising administering an amount of R(+)-N-propargyl-1-aminoindan or a pharmaceutically acceptable salt thereof.

The invention relates to the use of certain alpha-aminoamide derivatives in the treatment of RLS and addictive disorders. The compounds of this invention are able to reduce or even stop the symptoms of RLS and addictive disorders substantially without side effects.

The invention is directed to methods of treating Restless Leg Syndrome by administering iron complexes with specificed iron release rates or specified iron core size.

A method for the treatment of restless legs syndrome in a patient using a combination of a COMT-inhibitor, a decarboxylase inhibitor and a dopamine precursor.

The present invention describes a method of treating restless leg syndrome by eliminating venous reflux in an underlying vein. The malfunctioning vein can be removed or ablated by inserting a catheter into the vein that transmits sufficient energy to coagulate or ablate the lining of the vein causing it to permanently close, eliminating the source of venous reflux and the symptom of restless leg syndrome.

The present invention is directed to a method for treating symptoms associated with Restless Legs Syndrome (RLS). The method includes administering to a warm-blooded animal in need of such treatment a dose of ketamine sufficient to alleviate symptoms associated with RLS.

In a living body inspection apparatus to inspect RLS (Restless Legs Syndrome), a pulse interval is obtained from a pulse wave signal, thereby performing a frequency analysis of the obtained pulse interval using COM. From a result of the frequency analysis, the low frequency components ranging from 0.04 to 0.15 Hz and the high frequency components ranging from 0.15 to 0.4 Hz are extracted. As an index posterior to an age amendment, low frequency components (LF)/high frequency components (HF) is obtained, for instance. It is then determined whether LF/HF is equal to or greater than a predetermined determination value indicating RLS. For example, it is determined whether LF/HF is equal to or greater than 0.65, which suspects RLS. It is determined whether a signal is accurately calculated which indicates an activity of autonomic nerve. A state of RLS is determined using LF/HF.

A method of alleviating symptoms of restless legs syndrome, includes (a) fitting an apparatus to a leg of a person afflicted with the symptoms of restless legs syndrome during a period rest, where the apparatus includes means for retarding movement of a foot of the leg of the person as the foot moves from a first position towards a second position; and (b) before the period of rest, alternately moving the foot between the first position and the second position, where the apparatus retards movement of the foot as the foot moves from the first position towards the second position.

There is disclosed a method for the treatment or prevention of Extra Pyramidal syndrome (EPS), dystonia, restless legs syndrome (RLS) or periodic leg movement in sleep (PLMS) comprising the administration of an adenosine A2a receptor antagonist, alone or in combination with other agents useful for treating EPS, dystonia, RLS or PLMS; also claimed are pharmaceutical compositions consisting of an adenosine A2a receptor antagonist in combination with an antipsychotic agent, an anticonvulsant agent, lithium or an opioid.

The compound having the structural formula I

or a pharmaceutically acceptable salt thereof, is disclosed, as well as its use in the treatment of central nervous system diseases, in particular Parkinson's disease, Extra Pyramidal Syndrome, restless legs syndrome and attention deficit hyperactivity disorder, pharmaceutical compositions comprising it, and combinations with other agents.

A therapeutic drug for psychoneurotic disorders, which is useful for therapies of psychoneurotic disorders, especially restless legs syndrome is disclosed. The therapeutic drug for psychoneurotic disorders according to the present invention comprises as an effective ingredient an opioid κ receptor agonist compound (excluding pentazocine) such as (−)-17-(cyclopropylmethyl)-3,14β-dihydroxy-4,5α-epoxy-6β[N-methyl-trans-3-(3-furyl)acrylamide]morphinan hydrochloric acid salt.

This invention relates to a method of treating a disorder selected from OCD, agoraphobia, agoraphobia without history of panic disorder, specific phobia, social phobia, PTSD, restless legs syndrome, premenstrual dysphoric disorder, hot flashes, and fibromyalgia by administering a compound of the formula 1

or a pharmaceutically acceptable salt thereof, wherein:

• • R¹ is hydrogen, straight or branched alkyl of from 1 to 6 carbon atoms or phenyl; and
  • R² is straight or branched alkyl of from 4 to 8 carbon atoms, straight or branched alkenyl of from 2 to 8 carbon atoms, cycloalkyl of from 3 to 7 carbon atoms, alkoxy of from 1 to 6 carbon atoms, -alkylcycloalkyl, -alkylalkoxy, -alkyl OH, -alkylphenyl, -alkylphenoxy, or -substituted phenyl. The invention also relates to a method of treating the above disorders by administering the compound (3S,5R)-3-Aminomethyl-5-methyl-octanoic acid.

New aporphine derivatives are disclosed which have formula (I) and the physiologically acceptable salts thereof. Said derivatives may be used for the treatment of Parkinson's disease, hemicrania, restless legs syndrome (RLS), sexual dysfunction in men and women, hyperprolactemia and psychotic disorders, and/or evaluation of Parkinson's disease. Processes for the preparation of such derivatives are also disclosed.

The invention discloses a traditional Chinese medicine composition for treating restless legs syndrome and belongs to the technical field of traditional Chinese medicine compositions. The traditional Chinese medicine composition comprises the following components in parts by weight: 10-50 parts of astragalus, 5-30 parts of white paeony root, 5-10 parts of cassia twig, 5-10 parts of ginger, 5-15 parts of jujube, 5-20 parts of angelica, 10-30 parts of suberect spatholobus stem, 5-30 parts of lycopodium clavatum, 5-20 parts of radix achyranthis bidentatae, 10-30 parts of prepared rhizome of rehmannia, 10-30 parts of rhizoma dioscoreae, 5-30 parts of cornus officinalis, 5-30 parts of atractylis ovata, 5-30 parts of poria cocos, 5-30 parts of salvia miltiorrhizae, 5-15 parts of szechuan lovage rhizome, 5-10 parts of radix glycyrrhizae, 5-10 parts of centipede and 5-10 parts of scorpion. The traditional Chinese medicine composition provided by the invention has a remarkable pharmacological effect on restless legs syndrome; on the whole, the traditional Chinese medicine composition provided by the invention has the advantages of short treatment course, high cure rate (above 95%), remarkable curative effect and low cost in treating restless legs syndrome.

A device and method for treating restless leg syndrome by transmitting sound proximate the leg or legs of a patient with sound in the range of 20 to 100 Hertz, or 20 to 100 beats per second. The method may be accomplished using sound generators disposed within a pad or sleeve.

The present invention relates to a transdermal therapeutic system, comprising (a) a backing layer, (b) a solvent-based self-adhesive matrix layer containing rotigotine as active ingredient, and (c) a release liner, wherein the self-adhesive matrix layer has a coating weight of about 75-400 g/m² and comprises a reservoir layer containing about 9-25 wt.-% rotigotine based on the weight of the reservoir layer, a kit comprising two transdermal therapeutic systems of the present invention as well as a method for the preparation of the transdermal therapeutic system of the present invention. In addition, the present invention relates to a transdermal therapeutic system comprising rotigotine as active ingredient for use in the treatment of patients suffering from Parkinson's disease, Parkinson's plus syndrome, depression, fibromyalgia and the restless-legs syndrome and for use in the treatment or prevention of dopaminergic neuron loss or cognitive disorders by transdermal administration of rotigotine once or twice weekly, wherein the transdermal therapeutic system comprises a backing layer, a solvent-based rotigotine containing self-adhesive matrix layer as well as a release liner and is adapted to allow for the transdermal administration of therapeutically effective amounts of rotigotine for at least 3 days.